Table 3.
Placebo Group (n = 20) | RAY1216 (n = 20) | RAY1216 plus RTV (n = 20) | |
---|---|---|---|
All adverse events, n (%) | 8 (40%) | 3 (15%) | 5 (25%) |
Treatment-related adverse events, n (%) | 4 (20%) | 0 (0%) | 1 (5%) |
Severe adverse events, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |